Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JP Morgan Downgrades ResMed to Neutral

JP Morgan Downgrades ResMed to Neutral

JP Morgan analyst David Low downgrades ResMed (NYSE:RMD) from Overweight to Neutral.

August 12, 2022

1 minute read

JP Morgan analyst David Low downgrades ResMed (NYSE:RMD) from Overweight to Neutral.

Credit Suisse Maintains Neutral on Accolade, Raises Price Target to $11

October 7, 7:49 AM

Credit Suisse analyst Jonathan Yong maintains Accolade (NASDAQ:ACCD) with a Neutral and raises the price target from $9 to $11.

April 11, 10:40 AM

Understanding Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies…

July 11, 4:00 PM

Bridge Investment Group (NYSE:BRDG) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent…

December 6, 12:28 PM

Fresenius Medical Care (NYSE: FMS) said in a